Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Does not matter Crumbs the important thing is that you have learned from your experience and that if what you are doing is not working then consider doing something different.
Some people may not want to do things differently for various reasons and that is fine but to me important to have an open mind and be willing to adapt to different situations and just so pleased you have made some of the right calls lately.
PS just had a look at other board which I rarely do but notice you have B99 posting there.
You may be aware but he really is a top chartist so again imo worth listening to if he makes TA predictions.Even if he is an Aston Villa supporter 😂
Of course C11 you can jump from frying pan into fire so as Crumbs says we make our own decisions and live by the consequences.
Just in this case and having a fair idea where Crumbs may have been ( must be a coincidence in the rare earth space lol) putting his money it proved a wise decision but you run the risk of news dropping here but we are accept this.
This is all about judgement decisions as to where and when we think the SP may react and our attitude etc.No one can be sure of what may occur it us all about increasing the odds in your favour and learning from experience.
Imo Crumbs and others have judged it right so far and they can always buy back in and they are probably happy to pay more if necessary if they judge the news is merit worthy.
A pretty heartfelt and honest post by you which imo contains some considered points.
You were “ disappointed” with news along with several others whether based on the actual content ( which I thought a bit like the curates egg) or just as it was not as good as had been predicted.
The point you make about the Clatterbridge excitement being based on the mRNA Vax was obvious to all but especially if like me and you are based in the NW where we could see at first hand the BBC coverage.
Imo you absolutely made the right decision to reduce your position not just to save “ paper valuation” but to invest elsewhere to save compounding your losses.
Others will have different views which is fine but GLA whatever individuals decide to do
Evening Crumbs,
The post 2015 AGM drop was totally different imo and the final drop to 3p though trended by a couple of lower placings on the journey was brought about by CF distressed situation.
This to me like others have said been triggered by someone or several desperate to get out and possibly either distressed or in RGs case on a time deadline.
Appreciate the difficult situation many will be feeling at the moment but Vulpes and RM will equally not be happy and do think there will be a lot of pressure on SCLP to address the situation.
The Investor Meet platform mention is a clear indication that SCLP wish to engage with SH but maybe the “ heavy drop in the SP” has just caused them to pause in order to see it play out as I imagine their reason for engagement is not related to the selling.
Hi Crumbs,
I am pleased your other share ( presume begins with an M and I have a small holding there) responded so well to the interview.
Always good to press the rest button once in a while and if you believe that overall the news was good and that you have a better idea of the risk/ reward moving forward then that gives you confidence especially from these levels.
I have sat through a few Investor Meet presentations on other shares and whilst they may not have time to handle all the posters questions then generally they are more informative than the Pro active ones
Crumbs AB has highlighted the key issue it is the level of expectation bs the actual results.
As you say the non Ovarian results are very small cohorts so you should not make too many forward conclusions but LD did seem to switch focus from Moditope mono therapy to a more likely Combo approach so why was that as it appears a rest switch in focus and appeared to spook certain investors as evident by the selling since the news hit.
I take a different line that likes of RM and Vulpes will not be bothered as yes they will take a different view from many PIs but they will be concerned about the falling SP
Hi Crumbs and have to say hope you are feeling better as some of your recent posts have been heartfelt but at same time have raised some really good points of discussion.
Disappointing in response to the very high level of expectation that was anticipated by many investors on that next Modi update.So to expand.
There was no further significant shrinkage in moving the partial to a full response in tumour regression in HNC that some predicted.
There was no similar response in non Ovarian cancers to that one HNC trial patient that again some predicted would be “ inevitable”.
The trial recruitment numbers were very slow between the Feb and July update.
The comments regarding the main potential moving forward being using Modi as a Combination rather than a mono therapy after again some raising the bar based on mouse/ Trish result/ AGM comments.
Plus I feel the RNS covered a few areas not just the Modi update and was a bit if a catch all and not particularly well written as others have said.
My Tuppence worth for what it is worth.
I think SCLP recognised the need to bring in a more commercial CEO in CH and I thought he did OK but I also think that he saw himself as being the person to take SCLP onto the global stage and LD did not want him to get all the glory.Not because she resented anyone else getting the limelight but that she thinks no one understands or can explain her “ baby” as well as her.
After the “ power struggle” which she inevitably won she has found it difficult as anyone would to balance her responsibilities moving forward as SCLP is now a much different organisation in terms of size and complexity than the last time she was joint CEO.There is a long way to go but I could see signs in the RNS that shows a change is taking place.
The statement of prioritising the 2 platforms is imo clear evidence that there has been a strategic process going on within SCLP probably under the guidance of Cossery but also shows a willingness of LD to adapt and move forward.
I did think LD interview was lacklustre but that is my personal view and did affect sentiment based on not appearing as excited based on the heightened level of expectations that AB has already covered.
I am still very confident here but then again I have always considered the reward here to be significant and if the data proves compellling only then will I consider it stellar.
The results in Ovarian cancer were excellent and great to see a pathway for SCIB 1 but obviously the Modi mono therapy results in other cancers were disappointing but like AB I think that expectations were raised far too high based on AGM comments and the McM comments.
ATB
Hi TF,
Bermuda was just putting forward an alternative hypothesis which I believe has credence.The successful production and Approval of the mRNA Covid technology in a very short space of time backs Boris view of wanting to make the U.K. a Life Science superpower complete with a swift regulatory background.
Its main purpose is to attract incoming pharma investment hence the courting of Bion Tech.
Of course it should support SCLP and it has done so via the Innovate scheme but that is the difference. The U.K. Govt needs to support SCLP whereas the likes of Bion Tech support the U.K. Govt by providing investment not demanding it whilst the Govt provides a great regulatory background.
Until SCLP demonstrates via an RNS that for eg the Moditope platform can offer a comparable potential contribution to the likes of mRNA then we are simply speculating and we are still a very early stage drug development Company.
The development of the Covid Vaccine is a case in point the mRNA efforts got Approved and sold billions.The SCLP attempt although very promising did not get beyond p1.
Thanks Burble and as you say if Modi proves to be successful as we expect it could prove very valuable as a disruptive alternative as we know the benefits of a wider non personalised treatment in terms of value for money/ benefiting more patients etc.
But we need that update to conclude that we can offer that possibility and that is why the next news is so important.The significant mention and possible leaning of the U.K. Govt you highlight is of considerable interest here and indicative of the future but if results are good we will be well in the frame but I fully understand the concern of some if the Modi results are not as significant as we expect.
That is the dilemma we simply don’t know at this stage.
Morning,
Dracula for clarity we know Adrian had responded to the mRNA Vaccines as he was featured on the NW News Report along with Dr Rob Jones and Dr Sheena Khanduri, Medical Director of Clatterbridge who only commented on the mRNA Vaccine results.
But great that CO has given his thoughts and we look forward to the next Modi 1 update hopefully confirming that Modi I offers great potential as a cancer Vax treatment and gets equally good publicity.
Https://horizonteminerals.com/news/en_20230704_corporate-presentation.pdf
Try looking at Isocovax
https://ir.icosavax.com/static-files/a6a59617-d6ec-4475-a3d6-6cdd3acf86b9
Evening WF just seen the longer version of the link you provided so thanks for that.
Adrian who is quoted said that following his last scan the Vaccine had virtually eliminated his tumour so a great result for him
As you say Hallsworthy we know typical manu of virus contracts then the characterisation study can easily be in order of £5-6m and then you have the actual study itself so your £10-15m range is imo eminently feasible.
We should find out more with the Isocovax SEC filings which should provide more detail.